Orna Therapeutics is pioneering a new class of RNA therapeutics through its innovative engineered circular RNA (oRNA®) technology, which offers significant advantages over traditional linear RNA. This technology is designed to enhance the efficacy and delivery of RNA-based treatments, particularly in the fields of oncology, autoimmune diseases, and genetic disorders. Orna's proprietary lipid nanoparticle (LNP) delivery system enables targeted treatment to various sites in the body beyond the liver, facilitating the potential for addressing a broader range of diseases. The company’s panCAR™ in vivo CAR technology exemplifies this approach, allowing for the modification of immune cells directly within patients without the need for preconditioning regimens, thus streamlining the treatment process.

In addition to its oRNA® technology, Orna Therapeutics is advancing its SiTu Editing in the Marrow (STEM)™ platform, which combines oRNA® with a novel CRISPR genome editing system. This platform aims to correct genetic diseases such as sickle-cell disease and beta-thalassemia directly in the bone marrow, offering a more efficient alternative to existing ex vivo editing methods. Furthermore, Orna is collaborating with Merck to develop next-generation vaccine candidates, leveraging the durability and potency of its oRNA® platform. Overall, Orna Therapeutics is positioned to transform the landscape of RNA therapeutics with its innovative technologies and strategic focus on unmet medical needs.

United States

Orna Therapeutics is a biotechnology company reshaping RNA therapeutics. We are developing the leading circular RNA technology platform (oRNA®) and unprecedented lipid nanoparticle (LNP) delivery solutions – unlocking the therapeutic possibilities of circular RNA and pioneering the next chapter of safe and effective in vivo therapies for the treatment of disease.
Website: www.ornatx.com 

Orna Therapeutics

Company Details